



4Q 2017 and FY 2017 Fact Sheet

March 15, 2018

NASDAQ: XELA



Disclaimer

Forward Looking Statements

Certain statements included in this presentation are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may”, “should”, “would”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “continue”, “future”, “will”, “expect”, “outlook” or other similar words, phrases or expressions. These forward-looking statements include statements regarding our industry, future events, the estimated or anticipated future results and benefits of the recently consummated transaction between Exela Technologies, Inc., SourceHOV Holdings, Inc., and Novitex Holdings, Inc. (including the related transactions, the “Business Combination”), future opportunities for the combined company, and other statements that are not historical facts. These statements are based on the current expectations of Exela management and are not predictions of actual performance. These statements are based on the current expectations of Exela management and are not predictions of actual performance. These statements are subject to a number of risks and uncertainties regarding Exela’s businesses, and actual results may differ materially. These risks and uncertainties include, but are not limited to, changes in the business environment in which Exela operates and general financial, economic, regulatory and political conditions affecting the industries in which Exela operates; changes in taxes, governmental laws, and regulations; competitive product and pricing activity; failure to realize the anticipated benefits of the Business Combination, including as a result of a delay or difficulty in integrating the businesses of SourceHOV and Novitex or the inability to realize the expected amount and timing of cost savings and operating synergies of the Business Combination; and those factors discussed under the heading “Risk Factors” in Exela’s Proxy Statement dated June 26, 2017 (the “Proxy Statement”) filed with the Securities and Exchange Commission (“SEC”). In addition, forward-looking statements provide Exela’s expectations, plans or forecasts of future events and views as of the date of this communication. Exela anticipates that subsequent events and developments will cause Exela’s assessments to change. These forward-looking statements should not be relied upon as representing Exela’s assessments as of any date subsequent to the date of this presentation.

Combined Financial Information

This presentation includes quarterly, unaudited historical financial information for each of the four calendar quarters of 2016, each of the four calendar quarters of 2017 for Novitex and SourceHOV on a combined basis. This combined quarterly unaudited historical financial information does not include Quinpario Acquisition Corp. 2 as it was a special purpose acquisition company. Interest (impacting Net loss), Debt and addbacks to EBITDA are based on credit agreements in place before the Business Combination. No adjustment has been made to restate or reflect Exela’s new capital structure. This combined quarterly unaudited historical financial information is not necessarily indicative of what the actual results of operations would have been had the Business Combination taken place on January 1, 2016, nor are they indicative of the future consolidated financial condition, results of operations or cash flows of Exela.

Pro Forma Financial Information

This presentation includes unaudited pro forma financial information for the three months and full year ended December 31, 2017, as if the Business Combination had been consummated on January 1, 2016, based on certain estimates and assumptions that Exela management deems to be reasonable. This pro forma financial information may be revised as additional information becomes available. Therefore, it is possible that the actual adjustments will differ from the pro forma adjustments and it is possible that the difference may be material. The unaudited pro forma condensed combined financial statements are not necessarily indicative of what the actual results of operations would have been had the Business Combination taken place on the date indicated, nor are they indicative of the future consolidated results of operations of Exela.

Non-GAAP Financial Measure and Related Information

This presentation includes EBITDA, Further Adjusted EBITDA, and Further Adjusted Free Cash Flow – each of which is a financial measure that is not prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). Exela believes that these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to Exela’s financial condition and results of operations. Exela does not consider these non-GAAP measures in isolation or as an alternative to liquidity or financial measures determined in accordance with GAAP. A limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in Exela’s financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which expenses and income are excluded or included in determining these non-GAAP financial measures and therefore the basis of presentation for these measures may not be comparable to similarly-titled measures used by other companies. These non-GAAP measures should not be considered in isolation of, or as an alternative to, GAAP financial measures. For reconciliation of the comparable GAAP measures to these non-GAAP financial measures, see the Appendix to this presentation.

Exela Technologies, Inc. – Basis for pro forma financial information

1. Exela Technologies, Inc. (Exela), the accounting acquirer and successor of the business combination of Quinpario. Acquisition Corp. with SourceHOV Holdings, Inc. (SourceHOV) and Novitex Holdings, Inc. (Novitex) on July 12, 2017.”
2. The combined quarterly unaudited historical financial information included in this Presentation represents the combined historical financial information of Novitex and SourceHOV for periods prior to the Business Combination, but excludes QPAC as it was a special purpose acquisition company. Interest (impacting Net loss), Debt and addbacks to EBITDA are based on credit agreements in place before the Business Combination. No adjustment has been made to restate or reflect Exela's new capital structure for the quarters prior to the Business Combination.

Combined Quarterly Information – Exela Technologies, Inc.

Income Statement

(\$ in millions)

	Q1 2016	Q2 2016	Q3 2016	Q4 2016	Q1 2017	Q2 2017	Q3 2017	Q4 2017	FY 2016	FY 2017
Revenue										
Information and Transaction Processing Solutions (ITPS)	\$243.2	\$238.9	\$230.2	\$271.0	\$279.4	\$270.3	\$279.8	\$301.5	\$983.3	\$1,131.0
Healthcare Solutions (HS)	67.4	61.0	60.7	58.6	59.1	58.1	56.4	60.1	247.6	233.6
Legal and Loss Prevention Services (LLPS)	25.9	25.2	28.3	22.8	23.4	21.6	22.0	24.7	102.2	91.6
Total Revenue	336.5	325.0	319.1	352.5	361.9	350.0	358.2	386.3	1,333.1	1,456.3
Cost of Revenue (exclusive of depreciation and amortization)	242.7	228.7	229.7	256.0	261.9	257.0	271.1	289.9	957.1	1,079.9
Gross Profit	93.7	96.3	89.5	96.5	100.0	92.9	87.1	96.4	376.0	376.4
<i>Gross Margin</i>	28%	30%	28%	27%	28%	27%	24%	25%	28%	26%
Selling, general and administrative expenses	44.9	47.0	41.5	46.8	51.6	49.4	106.5	106.5	180.2	313.9
<i>% of Revenue</i>	13%	14%	13%	13%	14%	14%	30%	28%	14%	22%
Adjusted EBITDA⁽¹⁾	63.9	63.5	56.3	64.7	62.7	64.3	55.5	62.7	248.5	245.2
<i>Adjusted EBITDA Margin⁽²⁾</i>	19%	20%	18%	18%	17%	18%	16%	16%	19%	17%
Further Adjusted EBITDA⁽³⁾									\$349.9	\$346.8
<i>Further Adjusted EBITDA Margin⁽⁴⁾</i>									26%	24%

Note: Financial results for Pro Forma FY 2016 does not include the first nine months of contribution from the TransCentra acquisition which closed on September 28, 2016.

- Adjusted EBITDA is presented as the combined financial information derived from standalone quarterly SourceHOV and Novitex financial statements. A reconciliation of Adjusted EBITDA to Net Loss is included on page [6].
- Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Revenue.
- Further Adjusted EBITDA is presented after including standalone synergies at both SourceHOV and Novitex, and combination synergies added to the Adjusted EBITDA. A reconciliation of Further Adjusted EBITDA to Net Loss is included on page [6].
- Further Adjusted EBITDA Margin is defined as Further Adjusted EBITDA divided by Revenue.

Combined Quarterly Information – Exela Technologies, Inc.

Current Assets and Current Liabilities⁽¹⁾

(\$ in millions)

	Q1 2016	Q2 2016	Q3 2016	Q4 2016	Q1 2017	Q2 2017	Q3 2017	Q4 2017
Cash and cash equivalents	\$46	\$45	\$44	\$46	\$56	\$56	\$27	\$39
Other current assets	323	296	316	294	298	300	303	309
Total current assets	\$369	\$341	\$361	\$339	\$354	\$355	\$330	\$348
Total current liabilities⁽²⁾	\$244	\$233	\$264	\$270	\$279	\$301	\$315	\$338

Note: Financial results for Pro Forma FY 2016 does not include the first nine months of contribution from the TransCentra acquisition which closed on September 28, 2016.

1) The summarized balance sheet information related to current assets and current liabilities is based on standalone quarterly SourceHOV and Novitex financial statements.

2) Total current liabilities is exclusive of current portion of long term debt.

Combined Financial Information – Exela Technologies, Inc.

Net Loss to Further Adjusted EBITDA Reconciliation

(\$ in millions)

	Q1 2016	Q2 2016	Q3 2016	Q4 2016	Q1 2017	Q2 2017	Q3 2017	Q4 2017	FY 2016	FY 2017
Net Loss	(\$12.9)	(\$17.7)	(\$16.7)	(\$19.9)	(\$25.4)	(\$27.9)	(\$130.5)	(\$58.7)	(\$67.2)	(\$242.4)
Taxes	(6.2)	(5.0)	(7.1)	(5.3)	(1.0)	(1.9)	(37.0)	(27.3)	(23.6)	(67.2)
Interest expense	39.0	38.5	39.6	40.2	38.3	40.0	38.3	36.7	157.3	153.4
Depreciation and amortization	28.4	31.6	29.1	31.2	31.0	31.1	29.2	28.1	120.2	119.5
EBITDA	\$48.3	\$47.4	\$44.8	\$46.1	\$43.0	\$41.5	(\$100.0)	(\$21.1)	\$186.7	(\$36.7)
Impairment of goodwill and other intangible assets								69.4	–	69.4
(Gain) / loss on extinguishment of debt							53.0	–	–	53.0
Optimization and restructuring expenses	10.2	11.0	4.7	10.0	5.9	10.2	20.9	11.0	36.0	47.9
Transaction and integration costs	0.4	0.7	0.7	1.5	10.0	7.3	79.3	2.4	3.3	99.0
Non-cash charges	2.1	0.7	1.8	2.9	0.1	2.0	2.3	2.3	7.5	6.7
New contract setup	0.9	1.5	2.0	0.9	1.1	0.9	–	–	5.3	2.0
Oversight and management Fees ⁽¹⁾	2.1	2.1	2.1	3.4	2.6	2.5	0.0	–	9.7	5.1
(Gain) / loss on derivative instruments								(1.3)	–	(1.3)
Adjusted EBITDA	\$63.9	\$63.5	\$56.3	\$64.7	\$62.7	\$64.3	\$55.5	\$62.7	\$248.5	\$245.2
Gain / (loss) on currency exchange									0.7	2.4
Combined merger adjustments ⁽²⁾									100.6	99.2
Further Adjusted EBITDA									\$349.9	\$346.8
Capex									51.5	42.4
Further Adjusted Free Cash Flow⁽³⁾									\$298.4	\$304.4

Note: Financial results for Pro Forma FY 2016 does not include the first nine months of contribution from the TransCentra acquisition which closed on September 28, 2016.

1. Oversight and management agreements with both sponsors were terminated on July 12, 2017.

2. Combined merger adjustments include both standalone synergies and combination synergies.

3. Defined as Further Adjusted EBITDA less total capital expenditures.

Details of Outstanding Equity Securities

Common: "XELA"

152,565,218 shares outstanding as of March 15, 2018 including the outstanding units.

Preferred:

4,569,233 shares outstanding as of March 15, 2018; Conversion ratio into common stock is currently 1.2226.

Warrants: "XELAW"

35.0 million public warrants outstanding (traded over the counter)

- Each warrant entitles its holder to purchase one-half of one share of Exela Common Stock at an exercise price of \$11.50 per share.
- Warrants are presently exercisable and will expire at 5:00 p.m., New York time on July 12, 2022 if not earlier redeemed.
- If the last sale price of Exela Common Stock equals or exceeds \$24.00 per share for any 20 trading days within a 30 trading day period Exela may, upon 30 days notice, redeem the outstanding warrants at a price of \$0.01 per warrant.

Outstanding Debt Instruments and Tax Attributes

Exela completed the Business Combination on July 12, 2017 at which time the following new debt instruments of \$1.35 billion were issued :

1. \$350 million Term Loan Facility - L + 750 bps, July 2023 maturity, 2.5% per annum mandatory amortization payable quarterly for initial 8 quarters, 5.0% per annum mandatory amortization thereafter payable in equal quarterly installments.
2. \$1 billion Senior Secured Notes - 10% coupon, July 2023 maturity, interest payable semi-annually starting 1/15/2018.
3. \$100 million Revolving Credit Facility - L + 700 bps initially, July 2022 maturity, undrawn revolver fees - 50bps, undrawn at close.

Note: Debt issuance costs are amortized using the effective interest rate method and is reported as interest expense. A total of \$70 million is being amortized over the term of the debt.

Details of Taxes and NOL's

1. Exela paid \$6 million of cash taxes for full year 2017.
2. As of December 31, 2017, Exela had \$757 million of federal NOLs to offset the pre-tax income and approximately \$334 million was available post section 382 limitations.